A polymeric nanoparticle formulation of curcumin (NanoCurc) ameliorates CCl 4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation

Savita Bisht, Mehtab A. Khan, Mena Bekhit, Haibo Bai, Toby Cornish, Masamichi Mizuma, Michelle A. Rudek, Ming Zhao, Amarnath Maitra, Balmiki Ray, Debomoy Lahiri, Anirban Maitra, Robert A. Anders

Research output: Contribution to journalArticle

67 Scopus citations


Plant-derived polyphenols such as curcumin hold promise as a therapeutic agent in the treatment of chronic liver diseases. However, its development is plagued by poor aqueous solubility resulting in poor bioavailability. To circumvent the suboptimal bioavailability of free curcumin, we have developed a polymeric nanoparticle formulation of curcumin (NanoCurc) that overcomes this major pitfall of the free compound. In this study, we show that NanoCurc results in sustained intrahepatic curcumin levels that can be found in both hepatocytes and non-parenchymal cells. NanoCurc markedly inhibits carbon tetrachloride-induced liver injury, production of pro-inflammatory cytokines and fibrosis. It also enhances antioxidant levels in the liver and inhibits pro-fibrogenic transcripts associated with activated myofibroblasts. Finally, we show that NanoCurc directly induces stellate cell apoptosis in vitro. Our results suggest that NanoCurc might be an effective therapy for patients with chronic liver disease.

Original languageEnglish (US)
Pages (from-to)1383-1395
Number of pages13
JournalLaboratory Investigation
Issue number9
StatePublished - Sep 1 2011



  • carbon tetrachloride
  • cirrhosis
  • curcumin
  • cytokines
  • liver fibrosis
  • myofibroblasts
  • NanoCurct
  • polymeric nanoparticle

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this